Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazana
about
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialDolutegravir: clinical efficacy and role in HIV therapy.Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health ServiceRelationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis.Demographical, Viro-Immunological, Clinical and Therapeutical Characteristics of HIV-Infected Patients in an "Epidemiologically Unexplored" Region of Italy (Calabria Region): the CalabrHIV Cohort.Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialRole of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) studyAgeing with HIV: a multidisciplinary review.Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis.Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients.Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons.Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse EventsEfficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
P2860
Q28540037-DA936871-EA8A-4E8B-AAD7-699BD90233CCQ33725024-1084B0CF-A5E4-4CFC-8A00-CF4DFB0EC8E9Q34273315-53D791FE-6D5C-4FD4-BB4B-C67947BEBD14Q35630635-536FF840-A0FF-4977-A977-3085126F78F1Q36208301-45E8A5B7-9038-4922-B4D9-9DBA9873349EQ36303488-4953C731-8B20-44AB-827E-BEBD1B835152Q36309602-7BC695B6-2C6D-48F9-A225-F19A7EB4288AQ36311127-DF60B633-2238-4E6A-80A6-CA1A4B3384D3Q37562742-39314106-A903-438F-B02A-8BB22397FFD6Q38376451-D3316AF0-8EDD-44EF-B5CA-A3C255E907A2Q38490362-54F25730-8B09-46CC-A0F1-081D400E19CAQ38724967-74199628-4C5D-4921-A5AB-22D6CB2B1C49Q38818789-ED447C78-493B-40BE-A723-976D725DE8B4Q38883681-FA3CC0A8-BD71-42CB-A9D0-71598FB3D126Q38972140-2D90C870-96FE-4699-B560-B69372CC9F33Q40212933-FB747B6B-5C37-4F90-B9D9-B0836A5158D1Q40395175-FC1E204D-237D-47AD-B8CE-AA6DABCD35ABQ40566104-6CE8AB95-BCA2-4990-BF40-87EC5258BC1CQ41056086-E3F0D2B5-4400-44E8-AF30-8E79C641A740Q42198834-44CFC6E4-9EA5-43C4-ABDA-C7DA2E101403Q42242935-D83252D8-6471-4001-9CB9-35DCE88AAEE2Q44250503-69448DB5-471D-470B-AA7E-57D2FEAB7916Q50778858-A316B246-A1D0-4E23-8BB8-A98BF602E791
P2860
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazana
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety and feasibility of trea ...... ble treatment with two nucleos
@nl
Safety and feasibility of trea ...... rological suppression (Atazana
@en
type
label
Safety and feasibility of trea ...... ble treatment with two nucleos
@nl
Safety and feasibility of trea ...... rological suppression (Atazana
@en
prefLabel
Safety and feasibility of trea ...... ble treatment with two nucleos
@nl
Safety and feasibility of trea ...... rological suppression (Atazana
@en
P2093
P50
P356
P1476
Safety and feasibility of trea ...... rological suppression (Atazana
@en
P2093
Alessandro D'Avino
Annalisa Mondi
Letizia Sidella
Nicoletta Ciccarelli
Rita Murri
Salvatore Farina
P304
P356
10.1093/JAC/DKT007
P407
P50
P577
2013-01-30T00:00:00Z